VivoSeq
Oncology

Cancer of the Esophagus

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Cancer of the Esophagus is an early-stage landscape with 0 programs across 3 companies. The most active players are Eastern Cooperative Oncology Group, Radiation Therapy Oncology Group, Translational Oncology Research International.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

0 programs

PreclinicalRadiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalT

Translational Oncology Research International

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed20 · 71%
Unknown status4 · 14%
Terminated2 · 7%
Active, not recruiting1 · 4%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

28 trials

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03133650·12 enrolled
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
Completed·SWOG Cancer Research Network·Phase 2·NCT00004233·65 enrolled
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
Completed·UUniversity of Chicago·Phase 2·NCT00004127·35 enrolled
PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016900
Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
Completed·EEuropean Institute of Oncology·Phase 3·NCT00002897·240 enrolled
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
Completed·SWOG Cancer Research Network·Phase 2·NCT00012363·61 enrolled
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00030862
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003237·55 enrolled
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003864
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00002631·298 enrolled
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00020761·51 enrolled
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00004235·47 enrolled
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Completed·Alliance for Clinical Trials in Oncology·Phase 3·NCT00003118·56 enrolled
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Completed·TTranslational Oncology Research International·Phase 2·NCT00591123·38 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00002984·26 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)